USP Looks To Maximize Opportunity As China Builds Drug Standards
This article was originally published in PharmAsia News
Executive Summary
A relationship initiated in the wake of a fatal heparin scandal between USP and the China Pharmacopeia Commission is going strong, presenting opportunities for companies like Sanofi and China’s Tasly as the Middle Kingdom gets set to expand drug standards.